Jiri Sliva

Dr. Jiri Sliva

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2018 in Biomedical Papers
Verified
Journal Article
Open access
PDF file
LLLeos Landa
Leos Landa
JJJan Jurica
Jan Jurica
JSJiri Sliva
Jiri Sliva
MPMonika Pechackova
Monika Pechackova
RDRegina Demlova
Regina Demlova
The use of cannabis for medical purposes has been recently legalised in many countries including the Czech Republic. As a result, there is increased interest on the part of physicians and patients in many aspects of its application. This mini review briefly covers the main active substances of the cannabis plant and mechanisms of action. It focuses on two conditions, cancer pain and spasticity in multiple sclerosis, where its effects are well-documented. A comprehensive overview of a few cannabis-based products and the basic pharmacokinetics of marijuana's constituents follows. The review concludes with an outline for preparing cannabis (dried inflorescence) containing drug dosage forms that can be produced in a hospital pharmacy.

9 November 2021 in Viruses
Verified
Journal Article
Open access
PDF file
Jiří BeranJiří Beran
Jiří Beran
MŠMarián Špajdel
Marián Špajdel
JSJiri Sliva
Jiri Sliva
Since its licensing in 1971, the synthetic compound inosine pranobex has been effectively combating viral infections, including herpes zoster, varicella, measles, and infections caused by the herpes simplex virus, human papillomavirus, Epstein–Barr virus, cytomegalovirus, and respiratory viruses. With the emergence of SARS-CoV-2, new and existing drugs have been intensively evaluated for their potential as COVID-19 medication. Due to its potent immunomodulatory properties, inosine pranobex, an orally administered drug with pleiotropic effects, can, during early treatment, alter the course of the disease. We describe the action of inosine pranobex in the body and give an overview of existing evidence collected to support further efforts to study this drug in a rigorous clinical trial setup.

16 December 2020 in Pathogens
Verified
Journal Article
Open access
PDF file
Jiří BeranJiří Beran
Jiří Beran
MŠMarián Špajdel
Marián Špajdel
VKVěra Katzerová
Věra Katzerová
AHAlena Holoušová
Alena Holoušová
JMJan Malyš
Jan Malyš
JSJiri Sliva
Jiri Sliva
During the COVID-19 pandemic, the elderly population has been disproportionately affected, especially those in nursing homes (NH). Inosine pranobex (IP) has been previously demonstrated to be effective in treating acute viral respiratory infections. In three NH experiencing the SARS-CoV-2 virus epidemic, we started treatment with IP as soon as clients tested PCR+. In Litovel, CZ, the difference in case-fatality rate (CFR) for the PCR+ group using vs. not using IP was statistically significant, and the odds ratio (OR) was 7.2. When comparing all those taking IP in the three NH vs. the non-drug PCR+ group in Litovel, the odds ratio was lower for all three NH, but still significant at 2.9. The CFR in all three tested NHs, age range 75–84, compared to the CFR in all NHs in the Czech Republic, was significantly reduced (7.5% vs. 18%) (OR: 2.8); there was also a significant difference across all age groups (OR: 1.7). In our study with 301 residents, the CFR was significantly reduced (OR: 2.8) to 11.9% (17/142) in comparison to a study in Ireland with 27.6% (211/764). We think the effect of IP was significant in this reduction; nevertheless, these are preliminary results that need larger-scale trials on COVID-19 patients.

1 October 2005 in European Journal of Pharmacology
Verified
Journal Article
Closed access
MVMartin Votava
Martin Votava
LHLadislav Hess
Ladislav Hess
JSJiri Sliva
Jiri Sliva
MKMiloslav Kršiak
Miloslav Kršiak
VAViktoria Agová
Viktoria Agová

8 August 2006 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Open access
PDF file
MPMichaela Prochazkova
Michaela Prochazkova
TDTomas Dolezal
Tomas Dolezal
JSJiri Sliva
Jiri Sliva
MKMiloslav Krsiak
Miloslav Krsiak
Levels of cyclooxygenase‐2 (COX‐2) mRNA, but not those of COX‐1, were reported to be raised significantly after peripheral inflammation in the rat spinal cord. The aim of the present study was to ascertain whether this pattern of COX‐2 and COX‐1 expression applies also to other pain conditions induced by surgical procedure. Experiments were performed on two types of pain models. In a model of postoperative pain, 1 cm longitudinal incision was made through skin, fascia and muscle of the plantar aspect of the right hind paw in anaesthetized rats. In the second model, peripheral inflammation was induced by unilateral, intraplantar injection of carrageenan in the right hind paw. Carrageenan injection or skin incision produced marked and significant reduction of paw withdrawal latencies to noxious radiant heat stimuli after 2 and 6 hr. Under the acute inflammation 2 and 6 hr after carrageenan injection levels of COX‐2 mRNA were markedly raised (7.8 and 15.5 times; P<0,001, respectively) while spinal levels of COX‐1 mRNA were not significantly altered (n.s.). In contrast, spinal levels of COX‐2 mRNA were raised less markedly in a model of postoperative pain (4.9 times at 2 hr; P<0,001 and 2.9 times (n.s.) at 6 hr after surgery) whilst levels of COX‐1 mRNA in the lumbar spine were increased significantly (2.3 times; P<0,001) 6 hr after surgery. The present findings indicate that expression of COX‐2 mRNA in the spine is less dominant in postoperative pain than in inflammatory pain and that spinal COX‐1 mRNA is upregulated in postoperative pain.

15 December 2016 in Physiological Research
Verified
Journal Article
Closed access
LHL. Hess
L. Hess
MVM. Votava
M. Votava
JMJ. Málek
J. Málek
AKA. Kurzová
A. Kurzová
JSJiri Sliva
Jiri Sliva
Oxytocin is a hormone therapeutically used mainly for its peripheral effects during pregnancy in the uterus and breasts. However, additional central effects, i.e. anxiolytic effect, decreased level of social stress and increased empathy have been also observed. Hence, the aim of our study was to evaluate if nasal oxytocin can be used as anxiolytic substance in rhesus monkeys (n=20) and rabbits (n=20). Simultaneously, mean arterial blood pressure, arterial oxygen saturation of hemoglobin and pulse rate were monitored in all the evaluated animals. While rabbits lost righting reflex, monkeys developed a dose-dependent loss of aggressiveness and/or anxiety as evaluated by behavioral methods (aggressive behavior was classified as non-sedated - sedated - strongly sedated).